C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
28 Novembre 2023 - 1:00PM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced
that it will host a webcast on Tuesday, December 12, 2023 at 4:30
PM ET to present new Phase 1 dose escalation data for relapsed
refractory multiple myeloma from the ongoing Phase 1/2 clinical
trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential
treatment of relapsed/refractory multiple myeloma and
relapsed/refractory non-Hodgkin’s lymphoma.
To join the webcast, please visit this link or the “Events &
Presentations” page of the Investors section on the company’s
website at www.c4therapeutics.com. A replay of the webcast will be
archived and available following the event.
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is leveraging its TORPEDO® platform
to efficiently design and optimize small-molecule medicines that
harness the body’s natural protein recycling system to rapidly
degrade disease-causing proteins, offering the potential to
overcome drug resistance, drug undruggable targets and improve
patient outcomes. C4T is advancing multiple targeted oncology
programs to the clinic and expanding its research platform to
deliver the next wave of medicines for difficult-to-treat diseases.
For more information, please visit www.c4therapeutics.com.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
C4 Therapeutics (NASDAQ:CCCC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024